'I think this is significant, I think this is writing history,' Biogen CEO Michael Vounatsos says on the FDA's decision to approve the company's Alzheimer's drug.
CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is "fair."
The price of the drug is a reflection of "two decades of no innovation" and will also allow Biogen to further invest in its pipeline of medicines for other diseases, he said during an interview with CNBC's "
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Alzheimer's drug from Biogen, against experts' adviceThe approval comes after an independent panel to the FDA urged the agency to reject the drug, which will be sold under the name Aduhelm.
Read more »
The long road to approval of controversial Alzheimer's treatment from BiogenThe U.S. Food and Drug Administration on Monday approved the first treatment of Alzheimer's disease in nearly two decades, Biogen Inc's (BIIB.O) aducanumab, after a long development process including one large trial that failed to meet its goal.
Read more »
Richard Robinson, longtime Scholastic CEO, dead at 84Richard Robinson, who as the longtime head of Scholastic Inc. presided over such bestsellers as the “Harry Potter” novels and “The Hunger Games” series along with a wide range of educational materials, reading clubs and book fairs, has died. He was 84.
Read more »
Law Firm Quits MyPillow CEO Mike Lindell’s Dominion Lawsuit, Claims Lawyer Filed It Without PermissionLaw firm quits MyPillow CEO Mike Lindell’s Dominion lawsuit, claims lawyer filed it without permission
Read more »